Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900664 · ClinicalTrials.gov registry record · Phase 1
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 283
- Enrollment target
NCT02900664 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 283 participants.
The verdict
NCT02900664, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 283 participants
- Enrollment target
Study Summary
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
Interventions
- BIOLOGICAL PDR001
- BIOLOGICAL CJM112
- BIOLOGICAL ACZ885
- DRUG TMT212
- DRUG EGF816
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2016-08-23 |
| Est. Completion | 2021-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02900664
The ClinicalTrials.gov registry entry for NCT02900664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PDR001 is the first listed.
NCT02900664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02900664 about?
NCT02900664 is a clinical study titled "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)". The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combination...
What is the current status of trial NCT02900664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 283 participants. The study started on 2016-08-23. Estimated completion is 2021-03-17.
What interventions are being tested in trial NCT02900664?
The interventions under investigation include: PDR001 (BIOLOGICAL), CJM112 (BIOLOGICAL), ACZ885 (BIOLOGICAL), TMT212 (DRUG), EGF816 (DRUG).
Who is sponsoring clinical trial NCT02900664?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.